EMA's Committee for Medicinal Products for Human Use (CHMP) at its 8-11 meeting. In December 2025, it recommended the approval of seven new drugs: Anktiva (nogapendekin alfa inbakicept), Aumseqa (aumolertinib), deluxemmip, Myqorzo (aficamten), mNexspike (COVID-19 mRNA vaccine), Gotenfia (golimumab) and Ranluspec (ranibizumab). These drugs are intended for the treatment of diseases such as non-small cell lung cancer, severe eosinophilic conditions, symptomatic obstructive hypertrophic cardiomyopathy, prevention of COVID-19, rheumatoid arthritis and neovascularization. The CHMP also issued positive recommendations to expand the therapeutic indications for drugs such as Arexvy (RSV vaccine), Bioplancovit, Aspaveli, Dovprela (pretomanid), Elucirem (gadopiclenol), Eylea (aflibercept), Mounjaro, Nucala (mepolizumab), Recarbrio, Simponi, Uplizna (inebilizumab) and Vueway, while some are awaiting a decision from the European Commission. Other drugs such as Blarcamesine (blarcamesine) for the treatment of Alzheimer's disease and Winrevair received related decisions or withdrawals of applications. Negatívne odporúčanie dostal liek Hetlioz (tasimelteon) na rozšírenie indikácie. Other updates include Vfend (voriconazole).